Cargando…

Association of Hemoglobin A(1c) Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative

IMPORTANCE: Consensus around an efficient second-line treatment option for type 2 diabetes (T2D) remains ambiguous. The availability of electronic medical records and insurance claims data, which capture routine medical practice, accessed via the Observational Health Data Sciences and Informatics ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vashisht, Rohit, Jung, Kenneth, Schuler, Alejandro, Banda, Juan M., Park, Rae Woong, Jin, Sanghyung, Li, Li, Dudley, Joel T., Johnson, Kipp W., Shervey, Mark M., Xu, Hua, Wu, Yonghui, Natrajan, Karthik, Hripcsak, George, Jin, Peng, Van Zandt, Mui, Reckard, Anthony, Reich, Christian G., Weaver, James, Schuemie, Martijn J., Ryan, Patrick B., Callahan, Alison, Shah, Nigam H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324274/ https://www.ncbi.nlm.nih.gov/pubmed/30646124 http://dx.doi.org/10.1001/jamanetworkopen.2018.1755

Ejemplares similares

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study
por: Wong, Carlos K. H., et al.
Publicado: (2019)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
por: Lee, Kyeong Won, et al.
Publicado: (2011)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
por: Peng, Xiaomei, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Development and validation of phenotype classifiers across multiple sites in the observational health data sciences and informatics network
por: Kashyap, Mehr, et al.
Publicado: (2020)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
por: Gamble, John-Michael, et al.
Publicado: (2018)

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
por: Taisiia Pavlovna, Tuchina, et al.
Publicado: (2021)

Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea
por: Cho, Nam-Jun, et al.
Publicado: (2021)

Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes
por: Lee, Suhrin, et al.
Publicado: (2020)

Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment
por: Okamura, Keisuke, et al.
Publicado: (2019)

U-Index, a dataset and an impact metric for informatics tools and databases
por: Callahan, Alison, et al.
Publicado: (2018)

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
por: Jeon, Won Kyeong, et al.
Publicado: (2021)

Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study
por: Lee, Kyung Ae, et al.
Publicado: (2022)

DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
por: Wong, Carlos K H, et al.
Publicado: (2020)

Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Jeon, Won Kyeong, et al.
Publicado: (2022)

Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2018)

Electronic phenotyping with APHRODITE and the Observational Health Sciences and Informatics (OHDSI) data network
por: Banda, Juan M., et al.
Publicado: (2017)

Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study
por: Cheng, Po-Chung, et al.
Publicado: (2019)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015)

Thiazolidinediones and bone fractures
por: Kaku, Kohei, et al.
Publicado: (2011)

Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
por: Horita, Shoko, et al.
Publicado: (2015)

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
por: Seong, Jong-Mi, et al.
Publicado: (2015)

Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA(1c) Levels in Japanese Patients with Type 2 Diabetes Mellitus
por: Hirao, Koichi, et al.
Publicado: (2012)

Response to Letter Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis”
por: Park, Kyung Woo
Publicado: (2022)

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
por: Wang, Fei, et al.
Publicado: (2017)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Thiazolidinediones: the Forgotten Diabetes Medications
por: Lebovitz, Harold E.
Publicado: (2019)

Informatics to support the IOM social and behavioral domains and measures
por: Hripcsak, George, et al.
Publicado: (2015)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Real‐world weight change among patients treated with glucagon‐like peptide‐1 receptor agonist, dipeptidyl peptidase‐4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence
por: Carls, G. S., et al.
Publicado: (2017)

Letter by Awadhesh Kumar Singh Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
por: Lim, Sun Woo, et al.
Publicado: (2015)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d9pcf35fhgkv7u5hnla7lms674